(Q43032664)

12 November 2017

title

A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy (English)

1 reference

12 November 2017

1 reference

1 reference

1 reference

12

0 references

author name string

Ming-Lung Yu

1

1 reference

12 November 2017

Shi-Ming Lin

2

1 reference

12 November 2017

Chuan-Mo Lee

3

1 reference

12 November 2017

Chia-Yen Dai

4

1 reference

12 November 2017

Wen-Yu Chang

5

1 reference

12 November 2017

Shinn-Cherng Chen

6

1 reference

12 November 2017

Li-Po Lee

7

1 reference

12 November 2017

Zu-Yau Lin

8

1 reference

12 November 2017

Ming-Yuh Hsieh

9

1 reference

12 November 2017

Liang-Yen Wang

10

1 reference

12 November 2017

Wan-Long Chuang

11

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 November 2006

1 reference

12 November 2017

1 reference

12 November 2017

volume

44

1 reference

12 November 2017

issue

5

1 reference

12 November 2017

page(s)

1086-1097

1 reference

Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival

12 November 2017

cites work

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

Sampling variability of liver fibrosis in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus infection

21 January 2018

1 reference

7 January 2021

The role of hepatitis B and C viruses in hepatocellular carcinoma in a hepatitis B endemic area. A case-control study

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.

1 reference

7 January 2021

Treatment of chronic hepatitis C in southern Taiwan

1 reference

7 January 2021

Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis.

1 reference

7 January 2021

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

1 reference

7 January 2021

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

1 reference

7 January 2021

Interferon therapy prolonged life expectancy among chronic hepatitis C patients

1 reference

7 January 2021

Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C.

1 reference

7 January 2021

High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study

1 reference

7 January 2021

Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C--a study of 527 patients at one establishment

1 reference

7 January 2021

Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study

1 reference

7 January 2021

A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C.

1 reference

7 January 2021

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C.

1 reference

7 January 2021

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C

1 reference

7 January 2021

Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers

1 reference

7 January 2021

Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease

1 reference

7 January 2021

Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups

1 reference

7 January 2021

Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection

1 reference

7 January 2021

Non-A, non-B chronic hepatitis is chronic hepatitis C: A sensitive assay for detection of hepatitis C virus RNA in the liver

1 reference

7 January 2021

Characterization of the genomic sequence of type V (or 3a) hepatitis C virus isolates and PCR primers for specific detection

1 reference

7 January 2021

Thrombocytopenia associated with hepatitis C viral infection

1 reference

7 January 2021

Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection

1 reference

7 January 2021

Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death.

1 reference

7 January 2021

Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

1 reference

7 January 2021

Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?

1 reference

7 January 2021

Prevention of hepatitis C virus-related hepatocellular carcinoma

1 reference

7 January 2021

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

1 reference

7 January 2021

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy

1 reference

7 January 2021

Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21363

1 reference

12 November 2017

1 reference